CDK 4/6 inhibitors for older women with HR-positive breast cancer
CDK 4/6 inhibitors for older women with HR-positive breast cancer
Reducing risk of breast cancer recurrence and death with increased dose density
Breast cancer therapy resistance mediated by FGFR amplification
The significance of CEACAM 5 in metastases of triple negative breast cancer
Results of the MONALEESA 7 trial
The REACT trial: Celecoxib vs placebo for primary breast cancer
Rationale and recruitment in the PARTNER trial
The role of axiliary node dissection in modern breast cancer surgery
Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy
ER positive breast cancer: Screening for clinical variables to predict late distance disease recurrence
Predicting late breast cancer recurrence with screening assays
The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone